- Revenue increased by 17.3% to $29.9 million.
- Delivered full fiscal year 2022 net income of $6.2 million, or $0.74 per diluted share.
Xian, China, Feb. 10, 2023 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, today announced its 2022 annual financial results for the fiscal year ended September 30, 2022.
FY 2022 Financial Highlights
- Total net revenues were US$29.9 million, representing a 17.3% increase from US$25.5 million for the same period in 2021.
- Gross profit increased by 32.5% to US$9.4 million from US$7.1 million for the same period in 2021.
- Gross margin was 31.5%, an increase by 3.6% from 27.9% for the same period in 2021.
- Revenues and gross profit of our bioactive food ingredient products increased by 48.5% and 61.4% compared to the same period of 2021.
- Net income increased by 35.4% to US$6.2 million in FY2022 from US$4.6 million for the same period in 2021.
- Diluted earnings per share (“EPS”) was $0.74, compared to $0.68 for the same period in 2021.
Management Commentary
“We are pleased to conclude fiscal 2022 with solid growth in both top and bottom lines compared to fiscal year 2021 despite challenges caused by volatile global environment including high inflation, supply chain disruption, and persistent outbreak of COVID-19 pandemic in last year.” Commented Richard (Yongwei) Hu, BON’s Chairman & CEO, “I would like to recognize our team for their contribution in navigating through these conditions by market strategy adjustment, disciplined cost management as well as pricing efforts. Thanks to their relentless effort and hard work, the gross profits of fragrance compound, health supplemental powder drinks and bioactive food ingredients increased by 27.3%, 10.4% and 61.4% from the prior year. Our net income grew 35.4% to $6.2 million.”
“Looking ahead to 2023, we expect the first-phase completion of our third production site - Yumen Plant in May 2023. Once up and running, Yumen Plant will add 150% revenue growth potential on an annualized basis. In addition, the successful launch of our new vegetable based probiotic powder drink for regulation and improvement of human's overall microbiome and digestive health, as well as natural based personal care product for female hygiene health will attract more natural health-conscious consumers and further drive revenue growth for BON. Last but not the least, the reopening of China will help boost our profit by alleviate pressures from supply chain and logistics. With our new Yumen plant, our new natural based products, along with post-COVID reopening, we are confident to deliver the sustainable growth and create lasting long-term value for our shareholders.”
FY 2022 Product Categories Summary: Growth vs. Prior Year
| Revenues increase | Gross Profits increase | |||
| Fragrance Compounds | 7.6 | % | 27.3 | % |
| Health Supplements (Powder Drinks) | 7.4 | % | 10.4 | % |
| Bioactive Food Ingredients | 48.5 | % | 61.4 | % |
Fragrance Compounds
- Revenue from sales of fragrance compound products increased by 7.6% to US$13.7 million from US$12.7 million for the same period in 2021. The increase was primarily attributable to 9.1% and 27.5% increases in average purchase order by customers and average selling price, partially offset by a decrease of 15.1% in sales volume due to the shortage of material supply.
- Gross profit from fragrance compound increased by 27.3% from US$3.0 million to US$3.8 million for the same period in 2021. The increase was primarily attributable to the above referenced factors.
Health Supplements (Powder Drinks)
- Revenue from sales of health supplement (powder drinks) products increased by 7.4% to US$7.1 million from US$6.7 million for the same period in 2021. The increase was attributable to 7.0% and 1.0% increases in average selling price and sales volume.
- Gross profit from health supplement (powder drinks) increased by 10.4% from US$2.1 million to US$2.3 million for the same period in 2021. The increase was primarily due to the above referenced factors.
Bioactive Food Ingredients
- Revenue from sales of bioactive food ingredient products increased by 48.5% to US$9.1 million from US$6.1 million for the same period in 2021. The increase was mainly attributable to 27.3% increase in sales volume due to strong customer demand and sales effort. The increase was also due to 17.4% increase in average selling price.
- Gross profit of our bioactive food ingredient products increased by 61.4% to $3.4 million from $2.1 million for the same period in 2021. This increase was primarily due to the above referenced reasons.
Selling expenses increased by $80,292, or approximately 58.0%, from $138,530 to $218,822 in the same period of 2021, mainly attributable to increase of advertising expense, salaries and social benefits on attending more trade shows as well as recruiting more sales staff.
Research and development (“R&D”) expenses increased by $175,508, or approximately 70.5%, from $249,050 in fiscal year 2021 to $424,558 in fiscal year 2022. The increase was mainly due to an increase of $140,504 in outsourcing R&D activities to external consulting firms.
Government subsidies received in the form of a grant and recognized as other operating income totaled $1,306,627 and $449,972 for the fiscal years ended September 30, 2022 and 2021, respectively.
Net income increased from $4.6 million in the fiscal year ended September 30, 2021 to $6.2 million in the same period of 2022.
Net cash used in operating activities during the year ended September 30, 2022 was $0.2 million compared to $4.1 million net cash provided by operating activities in the same period of 2021. The decrease was mainly attribute to a decrease of $3,632,922 in taxes payable primarily due to income and VAT tax paid in fiscal year 2022, an increase of $1,300,942 account receivable due to increased sales in the year ended September 30, 2022, and decrease in deferred revenue of $875,295 due to changes in customer payment pattern related with COVID-19.
Basic earnings per share (“EPS”) was $0.75, compared to $0.69 for the same period in 2021.
Diluted earnings per share (“EPS”) was $0.74, compared to $0.68 for the same period in 2021.
Subsequent Events
- On September 30, 2022, the Company announced there will be a delay to the completion of the construction work for its third production site – Yumen Plant to May 2023.
- On January 17, 2023, the Company closed a private offering with gross proceeds of $2,200,000, mainly to fund its new Yumen Plant and working capital for the new production facility.
Investor Conference Call and Webcast
A live webcast to discuss the Company’s FY 2022 financial results will be held on February 10, 2023, beginning at 9:00 a.m. EST. The webcast and accompanying slide presentation may be accessed on the Company’s IR website at https://www.bnlus.com/investorrelations-ep. The webcast also can be accessed by using the direct link: https://event.choruscall.com/mediaframe/webcast.html?webcastid=oKNXFTV5 . For those unable to listen to the live webcast, a recorded version will be available on the Company’s website after the event.
Pre-registration: https://dpregister.com/sreg/10175699/f5ecaa11e8
Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the operator. Participants may pre-register at any time, up to and including after the time that the call has started.
Those without internet access or unable to pre-register may dial in by calling:
U.S. Toll Free: 1-866-777-2509 | International Toll: 1-412-317-5413
About Bon Natural Life Limited
The Company focuses on the manufacturing of personal care ingredients, such as plant extracted fragrance compounds for perfume and fragrance manufacturers, natural health supplements such as powder drinks and bioactive food ingredient products mostly used as food additives and nutritional supplements by their customers. For additional information, please visit the Company’s website at www.bnlus.com.
Safe Harbor Statement
This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company's goals and strategies; the Company's future business development; product and service demand and acceptance; changes in technology; economic conditions; the growth of the natural, health and personal care market in China and the other international markets the Company plans to serve; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic and business conditions in China and the international markets the Company plans to serve and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward–looking statements to reflect events or circumstances that arise after the date hereof.
| For more information, please contact: | |
| In the United States: | |
| Maggie Zhang | Impact IR | Sophie Zhang | Impact IR |
| Phone: (646) 893-8916 | Phone: (917) 830-5219 |
| Email: maggie.zhang@irimpact.com | Email: sophie.zhang@irimpact.com |
BON NATURAL LIFE LIMITED AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
| As of September 30, | ||||||||
| 2022 | 2021 | |||||||
| ASSETS | ||||||||
| CURRENT ASSETS | ||||||||
| Cash | $ | 840,861 | $ | 1,903,867 | ||||
| Short-term investments | - | 1,703,314 | ||||||
| Accounts receivable, net | 6,784,307 | 6,152,807 | ||||||
| Inventories, net | 1,722,120 | 1,596,492 | ||||||
| Advance to suppliers, net | 4,091,990 | 4,094,312 | ||||||
| Acquisition deposit | 1,000,000 | 1,000,000 | ||||||
| Prepaid expenses and other current assets | 277,509 | 98,960 | ||||||
| TOTAL CURRENT ASSETS | 14,716,787 | 16,549,752 | ||||||
| Property, plant and equipment, net | 21,624,437 | 19,228,642 | ||||||
| Intangible assets, net | 366,167 | 411,056 | ||||||
| Right-of-use lease assets, net | 546,690 | 201,007 | ||||||
| Deferred tax assets, net | 2,768 | 22,342 | ||||||
| TOTAL ASSETS | $ | 37,256,849 | $ | 36,412,799 | ||||
| LIABILITIES AND EQUITY | ||||||||
| CURRENT LIABILITIES | ||||||||
| Short-term loans | $ | 2,424,587 | $ | 41,381 | ||||
| Current portion of long-term loans | 2,135,979 | 448,005 | ||||||
| Accounts payable | 214,585 | 380,385 | ||||||
| Due to related parties | 72,836 | 245,104 | ||||||
| Taxes payable | 1,239,708 | 5,052,018 | ||||||
| Deferred revenue | 188,745 | 1,096,101 | ||||||
| Accrued expenses and other current liabilities | 114,431 | 41,711 | ||||||
| Finance lease liabilities, current | 26,285 | 161,286 | ||||||
| Operating lease liability, current | 230,182 | 62,871 | ||||||
| TOTAL CURRENT LIABILITIES | $ | 6,647,338 | $ | 7,528,862 | ||||
| Long-term loans | 189,813 | 2,173,532 | ||||||
| Finance lease liabilities, noncurrent | - | 28,953 | ||||||
| Operating lease liability, noncurrent | 327,202 | 146,703 | ||||||
| TOTAL LIABILITIES | 7,164,353 | 9,878,050 | ||||||
| COMMITMENTS AND CONTINGENCIES | ||||||||
| EQUITY | ||||||||
| Ordinary shares, $0.0001 par value, 500,000,000 shares authorized, 8,396,226 and 8,330,000 shares issued and outstanding as of September 30, 2022 and 2021, respectively | $ | 840 | $ | 833 | ||||
| Additional paid in capital | 15,711,450 | 15,540,433 | ||||||
| Statutory reserve | 1,804,116 | 1,050,721 | ||||||
| Retained earnings | 14,676,769 | 9,192,676 | ||||||
| Accumulated other comprehensive income | (2,631,171 | ) | 222,221 | |||||
| TOTAL BON NATURAL LIFE LIMITED SHAREHOLDERS’ EQUITY | 29,562,004 | 26,006,884 | ||||||
| Non-controlling interest | 530,492 | 527,865 | ||||||
| TOTAL SHAREHOLDERS’ EQUITY | 30,092,496 | 26,534,749 | ||||||
| TOTAL LIABILITIES AND EQUITY | $ | 37,256,849 | $ | 36,412,799 | ||||
BON NATURAL LIFE LIMITED AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME
| For the Years Ended September 30, | ||||||||||||
| 2022 | 2021 | 2020 | ||||||||||
| REVENUE | $ | 29,908,561 | $ | 25,494,564 | $ | 18,219,959 | ||||||
| COST OF REVENUE | (20,484,996 | ) | (18,382,637 | ) | (13,017,646 | ) | ||||||
| GROSS PROFIT | 9,423,565 | 7,111,927 | 5,202,313 | |||||||||
| OPERATING EXPENSES | ||||||||||||
| Selling expenses | (218,822 | ) | (138,530 | ) | (161,719 | ) | ||||||
| General and administrative expenses | (2,239,967 | ) | (1,323,726 | ) | (1,367,070 | ) | ||||||
| Research and development expenses | (424,558 | ) | (249,050 | ) | (205,359 | ) | ||||||
| Total operating expenses | (2,883,347 | ) | (1,711,306 | ) | (1,734,148 | ) | ||||||
| INCOME FROM OPERATIONS | 6,540,218 | 5,400,621 | 3,468,165 | |||||||||
| OTHER INCOME (EXPENSES) | ||||||||||||
| Interest income | 1,392 | 3,207 | 714 | |||||||||
| Interest expense | (446,884 | ) | (417,266 | ) | (329,102 | ) | ||||||
| Unrealized foreign transaction exchange gain (loss) | 18,831 | (45,124 | ) | (248 | ) | |||||||
| Gain on disposal of fixed assets | - | - | 20,150 | |||||||||
| Government subsidies | 1,306,627 | 449,972 | 362,187 | |||||||||
| Income from short-term investments | 20,343 | 565 | - | |||||||||
| Other income | 68,922 | 38,409 | 132,713 | |||||||||
| Total other income, net | 969,231 | 29,763 | 186,414 | |||||||||
| INCOME BEFORE INCOME TAX PROVISION | 7,509,449 | 5,430,384 | 3,654,579 | |||||||||
| INCOME TAX PROVISION | (1,267,025 | ) | (820,931 | ) | (556,262 | ) | ||||||
| NET INCOME | 6,242,424 | 4,609,453 | 3,098,317 | |||||||||
| Less: net income attributable to non-controlling interest | 4,936 | 18,650 | 71,644 | |||||||||
| NET INCOME ATTRIBUTABLE TO BON NATURAL LIFE LIMITED | $ | 6,237,488 | $ | 4,590,803 | $ | 3,026,673 | ||||||
| OTHER COMPREHENSIVE INCOME (LOSS) | ||||||||||||
| Total foreign currency translation adjustment | (2,855,701 | ) | 612,806 | 450,234 | ||||||||
| TOTAL COMPREHENSIVE INCOME | 3,386,723 | 5,222,259 | 3,548,551 | |||||||||
| Less: comprehensive income attributable to non-controlling interest | 2,627 | 21,133 | 81,737 | |||||||||
| COMPREHENSIVE INCOME ATTRIBUTABLE TO BON NATURAL LIFE LIMITED | $ | 3,384,096 | $ | 5,201,126 | $ | 3,466,814 | ||||||
| EARNINGS PER SHARE | ||||||||||||
| Basic | $ | 0.75 | $ | 0.69 | $ | 0.58 | ||||||
| Diluted | $ | 0.74 | $ | 0.68 | $ | 0.58 | ||||||
| WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING | ||||||||||||
| Basic | 8,360,774 | 6,615,833 | 5,210,649 | |||||||||
| Diluted | 8,396,064 | 6,706,235 | 5,210,649 | |||||||||
BON NATURAL LIFE LIMITED AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
| For the Years Ended September 30, | ||||||||||||
| 2022 | 2021 | 2020 | ||||||||||
| Cash flows from operating activities | ||||||||||||
| Net income | $ | 6,242,424 | $ | 4,609,453 | $ | 3,098,317 | ||||||
| Adjustments to reconcile net income to cash provided (used in) by operating activities | ||||||||||||
| Allowance for doubtful accounts | 116 | 2,948 | 22,137 | |||||||||
| Depreciation and amortization | 218,526 | 228,547 | 230,597 | |||||||||
| Inventory reserve (recovery) reverse | (138,354 | ) | (312,532 | ) | 29,539 | |||||||
| Deferred income tax | 19,012 | 29,109 | (7,751 | ) | ||||||||
| Amortization of operating lease right-of-use assets | 150,978 | 58,147 | - | |||||||||
| Amortization of stock-based compensation | 170,883 | 44,910 | - | |||||||||
| Unrealized foreign currency exchange loss (gain) | (18,831 | ) | 45,124 | 248 | ||||||||
| Gain on disposal of property and equipment | (725 | ) | - | (20,150 | ) | |||||||
| Changes in operating assets and liabilities: | ||||||||||||
| Accounts receivable | (1,300,942 | ) | (89,543 | ) | (284,546 | ) | ||||||
| Inventories | (157,709 | ) | (209,011 | ) | 1,636,321 | |||||||
| Advance to suppliers, net | (407,022 | ) | (399,262 | ) | (3,021,739 | ) | ||||||
| Prepaid expenses and other current assets | (265,446 | ) | 2,642 | 72,116 | ||||||||
| Accounts payable | (141,927 | ) | (969,414 | ) | (1,982,205 | ) | ||||||
| Operating lease liabilities | (147,812 | ) | (49,648 | ) | - | |||||||
| Taxes payable | (3,632,922 | ) | 410,716 | 2,662,542 | ||||||||
| Deferred revenue | (875,295 | ) | 684,030 | 161,045 | ||||||||
| Accrued expenses and other current liabilities | 97,925 | (33,092 | ) | 46,605 | ||||||||
| Net cash (used in) provided by operating activities | (187,121 | ) | 4,053,124 | 2,643,076 | ||||||||
| Cash flows from investing activities | ||||||||||||
| Purchase of short-term investments | (5,097,816 | ) | (2,159,920 | ) | - | |||||||
| Proceeds upon redemption of short-term investments | 6,776,385 | 470,082 | - | |||||||||
| Purchase of property and equipment | (27,695 | ) | (51,878 | ) | (31,885 | ) | ||||||
| Proceeds from sales of property and equipment | 1,613 | - | - | |||||||||
| Capital expenditures on construction-in-progress | (4,708,138 | ) | (4,432,941 | ) | (4,301,103 | ) | ||||||
| Purchase of intangible assets | - | (269,088 | ) | - | ||||||||
| (Payment) refund of acquisition deposit | - | (1,000,000 | ) | 1,329,945 | ||||||||
| Net cash used in investing activities | (3,055,651 | ) | (7,443,745 | ) | (3,003,043 | ) | ||||||
| Cash flows from financing activities | ||||||||||||
| Net proceeds from issuance of Ordinary Shares in initial public offerings | - | 11,271,480 | - | |||||||||
| Proceeds from exercise of stock options | 140 | |||||||||||
| Proceeds from short-term loans | 2,631,890 | 1,257,225 | 2,033,570 | |||||||||
| Proceeds from long-term loans | 578,343 | 1,245,871 | 319,342 | |||||||||
| Repayment of short-term loans | (40,780 | ) | (2,563,433 | ) | (2,872,778 | ) | ||||||
| Repayment of long-term loans | (637,147 | ) | (2,522,101 | ) | - | |||||||
| (Repayment of) proceeds from borrowings from related parties | (96,969 | ) | (2,262,378 | ) | 1,067,808 | |||||||
| (Repayment of) proceeds from third party loans | - | (721,484 | ) | 238,133 | ||||||||
| (Repayment of) principal from finance lease | (173,961 | ) | 169,153 | (392,030 | ) | |||||||
| Payment for deferred initial public offering costs | - | (521,651 | ) | (281,553 | ) | |||||||
| Net cash provided by financing activities | 2,261,516 | 5,352,682 | 112,492 | |||||||||
| Effect of changes of foreign exchange rates on cash | (81,750 | ) | (111,300 | ) | 6,810 | |||||||
| Net (decrease) increase in cash | (1,063,006 | ) | 1,850,761 | (240,665 | ) | |||||||
| Cash, beginning of year | 1,903,867 | 53,106 | 293,771 | |||||||||
| Cash, end of year | $ | 840,861 | $ | 1,903,867 | $ | 53,106 | ||||||
| Supplemental disclosure of cash flow information | ||||||||||||
| Cash paid for interest expense | $ | 446,884 | $ | 417,266 | $ | 276,671 | ||||||
| Cash paid for income tax | $ | 2,290,393 | $ | 2,411 | $ | - | ||||||
| Supplemental disclosure of non-cash investing and financing activities | ||||||||||||
| Amortization of share-based compensation for initial public offering services | $ | - | $ | 422,221 | $ | 211,112 | ||||||
| Right-of-use assets obtained in exchange for operating lease obligations | $ | 546,323 | $ | 257,564 | $ | - | ||||||
